Ascendis Pharma ( ASND )

N/A

Clinical Trials (1)

NCT05775523A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

N/A

Palopegteriparatide

N/A

Clinical Trials (1)

NCT05654701Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

N/A

Palopegteriparatide

N/A

Clinical Trials (1)

NCT07264634A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

N/A

A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia

N/A

Clinical Trials (1)

NCT03875534A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia

N/A

No intervention

N/A

Clinical Trials (1)

NCT05820672A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

N/A

Palopegteriparatide

Growth Hormone Deficiency (GHD)

N/A

Clinical Trials (1)

NCT07345494A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

N/A

TransCon Treprostinil

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03803163A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers

Phase 1

ACP-001

Healthy

Phase 1

Clinical Trials (1)

NCT01010425Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)

Phase 1

TransCon IL-2 β/γ

Advanced Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT05081609A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Phase 1/2

TransCon TLR7/8 Agonist

Advanced Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT04799054A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2

ACP-001

Phase 2

Clinical Trials (1)

NCT01947907Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Phase 2

TransCon CNP

Phase 2

Clinical Trials (1)

NCT05246033A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia

Phase 2

TransCon PTH

Adult Growth Hormone Deficiency

Phase 2

Clinical Trials (1)

NCT04009291A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Phase 2

TransCon TLR7/8 Agonist

Head and Neck Neoplasms

Phase 2

Clinical Trials (1)

NCT05980598TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

ACP-001

Phase 2

Clinical Trials (1)

NCT01247675A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency

Phase 2

TransCon CNP

Phase 2

Clinical Trials (1)

NCT04085523A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

Phase 2

Navepegritide

Phase 2

Clinical Trials (1)

NCT06732895A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

Phase 2

Navepegritide

Phase 2

Clinical Trials (1)

NCT06079398A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

Phase 2

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Phase 2

Clinical Trials (1)

NCT06433557A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

Phase 2

Lonapegsomatropin

Turner Syndrome

Phase 2

Clinical Trials (1)

NCT05690386A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Phase 2

TransCon CNP

Phase 2/3

Clinical Trials (1)

NCT05929807A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

Phase 2/3

TransCon CNP

Growth Hormone Deficiency, Pediatric

Phase 2/3

Clinical Trials (1)

NCT05598320A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia

Phase 2/3

TransCon hGH

Phase 3

Clinical Trials (1)

NCT03344458A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

Phase 3

Lonapegsomatropin

Phase 3

Clinical Trials (1)

NCT04615273A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Phase 3

TransCon PTH

Growth Hormone Deficiency, Pediatric

Phase 3

Clinical Trials (1)

NCT04701203A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

Phase 3

Once weekly subcutaneous injection of TransCon hGH

Phase 3

Clinical Trials (1)

NCT02781727A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Phase 3

Lonapegsomatropin

Adult Growth Hormone Deficiency

Phase 3

Clinical Trials (1)

NCT05171855A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Phase 3

Palopegteriparatide Experimental Arm

Growth Hormone Deficiency, Pediatric

Phase 3

Clinical Trials (1)

NCT07081997A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Phase 3

Lonapegsomatropin [SKYTROFA®]

Turner Syndrome

Phase 3

Clinical Trials (1)

NCT07221851Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Phase 3

TransCon hGH

Phase 3

Clinical Trials (1)

NCT03305016A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

Phase 3

TransCon hGH